Date	Event	Description
12 January 2018	New citation required and conclusions have changed	New co‐author joined the team: Dr Celina Gialdini. Nine new studies included (two of sildenafil versus placebo, three of labetalol versus methyldopa, one of nifedipine versus methyldopa, one of nifedipine versus labetalol, one of amlodipine versus furosemide and a three‐arm trial of nifedipine versus labetalol versus methyldopa). Twenty new studies were excluded with reasons and there are eight new ongoing trials. Five studies Finland 1988b; France 1990; Hong Kong 1993; India 2011; Spain 1988, excluded in previous versions of this review for not reporting clinical outcomes, are now included, specifying that they do not contribute data. Figure 1: study flow diagram was added. The introduction was updated in line with new definitions for pre‐eclampsia, and the inclusion of new agents (amlodipine and sildenafil). Common side‐effects of each family of drugs were added in the introduction section "How the intervention might work". Conclusions changed: Implications for practice now reflect the benefits of avoiding hypertensive crises and use of additional antihypertensives, and the possible benefits of beta‐blockers and calcium channel blockers on avoiding a hypertensive crisis.
13 September 2017	New search has been performed	Search updated.